Clinical trial NCT05477069: Feasibility Study of an Innovative Medical Device for Sampling the Contents of the Small Intestine.
Official title: Feasibility Study of an Innovative Medical Device for Sampling the Contents of the Small Intestine. Functional Evaluation on the Transit of Healthy Volunteers. A First in Man, Prospective, Monocentric, Not Randomized Study.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Healthy Volunteers
Keywords: Innovative medical device
Microbiota
Biochemically controlled capsule
Intestinal fluid sampling
Lead sponsor: University Hospital, Grenoble
Sponsor class: OTHER
Collaborators: name: Clinical Investigation Centre for Innovative Technology Network
name: Pelican Health
First posted: 2022-07-28
Enrollment: 16
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DEVICE_FEASIBILITY

Brief summary: For the first time in the world, the objective of this study is to evaluate on healthy volunteers, an innovative medical device for the capture of intestinal liquid.This medical device is not yet CE marked.

Detailed description: This medical device consists of a standard pill made of 3 capsules for the collection of intestinal microbiota. The pill is ingested by the volunteer and multi-omics analysis will be performed on intestinal fluid samples from the capsules and also on faeces.

First in man, involving a medical device, prospective, monocentric, not randomized, not controlled and open-label study.

Eligibility criteria: Inclusion Criteria:

* Able to understand the study and the associated instructions
* Aged ≥18 years and ≤65 years
* Fasting with water and food for at least 10 hours
* BMI between ≥20 and ≤30 kg/m².
* Transit evaluated at 1 to 3 bowel movements/day
* Maintain regular physical activity and eating habits for the duration of the study
* Affiliated with a social security plan
* Have a freezer in their home and at work, if applicable
* Volunteer staying in the Isère department during the collection of the faeces (from 96 hours to 15 days max)
* Having signed the informed and collection consent

Exclusion Criteria:

Subject :

* with medical treatment (except oral contraception and/or probiotics and related products)
* with lactose and fructose intolerance
* with of gastroparesis
* who had a colonoscopy preparation up to 1 month prior to inclusion
* in the exclusion period of another clinical investigation,
* who receive more than 4500 euros of compensation due to his participation in other biomedical research in the 12 months preceding this study
* who cannot be contacted in case of emergency
* who has taken during the 15 days prior to inclusion and/or is scheduled to take the following treatments during the study: antidepressants, anxiolytics, antiparkinsonian agents, neuroleptics, antibiotics and prebiotics
* who has taken during the previous 7 days: at least once a treatment for irritable bowel syndrome (antispasmodics,..) or for constipation (laxative) or for diarrhea
* with a known food allergy
* who have to undergo colon surgery
* with intestinal obstruction history
* with hepatic, cardiac, congenital or renal comorbidity
* with long-standing diabetes
* with an inflammatory disease of the digestive tract, a history of digestive surgery
* who have been treated with radiotherapy or who have taken anti-inflammatory drugs for a long time
* with gastric fullness
* with known or suspected obstruction of the gastrointestinal tract (including known inflammatory bowel or intestinal diverticula)
* with presence of swallowing disorders or Zencker's diverticulum
* with nausea, deviated nasal septum
* with contraindications to esophageal tube placement (chronic esophageal pathology)
* drug or alcohol abuse (3 units for men and 2 units for women according to WHO criteria)
* with a known allergy to silicone or to iodine
* refusing medical imaging or surgery (in case of non-recovery of the capsule)
* protected person concerned by the articles L1121-5 to L1121-8 of the Public Health Code
* absence of highly effective contraception for women with childbearing capacity until the end of the cycle following the end of participation in the trial

Primary outcomes:
measure: Demonstrate the absence of adverse events (safety of the medical device) and that the device is analyzable (performance of the medical device).
timeFrame: From 96 hours to 15 days
Secondary outcomes:
measure: Number and grade of adverse events collected during the capsule collection period
timeFrame: From 96 hours to 15 days
measure: Number of capsules found to verify that the medical device passes through the human body
timeFrame: From 96 hours to 15 days
measure: Verify that the medical device has captured intestinal fluid
timeFrame: From 96 hours to 15 days
measure: Verify that the medical device has opened in the intestine
timeFrame: From 96 hours to 15 days
measure: Absence of tears and detachment of the various elements of the capsule
timeFrame: From 96 hours to 15 days
measure: Metagenomic analysis using 16s sequencing will provide data to establish differences in the gut microbiota profile/composition between capsule and faecal contents.
timeFrame: From 96 hours to 15 days
measure: Medical device usability and acceptability : descriptive analysis
timeFrame: From 96 hours to 15 days
measure: Obtain an overview of the sample's functional potential and identify biomarkers (organisms) via culturomics, on samples from up to 2 subjects.
timeFrame: From 96 hours to 2 months
Other outcomes:
Locations:
city: Grenoble
country: France
facility: University Hospital Grenoble Alpes
Study officials:
affiliation: University Hospital, Grenoble
name: Nicolas Matthieu, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References: